相关实验视频
Updated: Jan 16, 2026

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
Published on: July 18, 2016
辅助化疗治疗第一阶段卵巢清细胞癌
Naoki Horikawa1, Yoshihide Inayama1, Miki Otsuki1
1Departments of Obstetrics and Gynecology, Kurashiki Central Hospital, Okayama, Kyoto University Hospital and Kyoto Medical Center, Kyoto, Kitano Hospital and Osaka Red Cross Hospital, Osaka, Nagahama Red Cross Hospital, Shiga, Hyogo Prefectural Amagasaki General Medical Center, Hyogo, Toyooka Hospital, Hyogo, and Shizuoka General Hospital, Shizuoka, Japanese Red Cross Wakayama Medical Center, Wakayama, and the Department of Gynecology, Shiga General Hospital, Shiga, Japan.
术后化疗改善了I期卵巢清细胞癌患者的无病生存率. 这一发现有助于在手术后决定辅助化疗.
科学领域:
- 妇科瘤学 妇科瘤学
- 手术瘤学手术瘤学
- 化疗研究 化疗研究
背景情况:
- 卵巢清细胞癌 (OCCC) 是卵巢癌的一个独特的亚型.
- 对早期OCCC的最佳辅助治疗策略仍在调查中.
- 了解化疗在早期疾病中的作用对于患者的治疗结果至关重要.
研究的目的:
- 评估I期卵巢清细胞癌患者的术后化疗和预后之间的关联.
- 确定基于的多剂化学疗法对无病生存期 (DFS) 和整体生存期 (OS) 的影响.
主要方法:
- 回顾性队列研究,包括283名患有I期OCCC的患者接受手术 (2005-2019).
- 排除标准包括手术前淋巴结扩大和节育手术.
- 倾向性得分重叠权重被用于调整混因素.
主要成果:
- 与对照组 (0.77) 相比,化疗组 (0.86) 的五年DFS更高.
- 调整后的分析显示,接受化疗的患者复发的风险显著降低 (DFS的加权HR:0.43;P=.026).
- 两组之间没有观察到总生存时间的显著差异 (加权HR:0.68;P=.40).
结论:
- 术后基于的多剂化学疗法与I期卵巢清细胞癌的无疾病生存率的改善有关.
- 这些结果为在这个患者群体中关于辅助化疗的共享决策提供了有价值的数据.
相关概念视频
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Targeted Cancer Therapies
There are several types of targeted therapies against...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

